Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2009 - 2024)

Alnylam Pharmaceuticals (ALNY) has 16 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q3 2024.

• Quarterly Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.0 million (down 99.48% YoY) and the FY2023 annual result came in at $188.2 million, down 2.9% from the prior year.
• Non-Current Deffered Revenue fell to $1.0 million in Q3 2024, from $2.4 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $306.1 million in Q1 2020 to a low of $1.0 million in Q3 2024.
• A 5-year average of $180.9 million and a median of $191.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue jumped 63942.68% — and 2024, when it tumbled 99.48%.
• Tracing ALNY's Non-Current Deffered Revenue over 5 years: stood at $225.1 million in 2020, then tumbled by 32.31% to $152.4 million in 2021, then climbed by 27.19% to $193.8 million in 2022, then declined by 2.9% to $188.2 million in 2023, then tumbled by 99.46% to $1.0 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q3 2024), $2.4 million (Q2 2024), and $185.5 million (Q1 2024), per Business Quant data.